Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

- PMLiVE

Andrew Gengos joins ImmunoCellular as CEO

Will lead company as it initiates phase II trials investigating brain tumour vaccine

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

- PMLiVE

Novartis calls for improvements to UK clinical trial system

Says cost of running studies in the country undermines its attractiveness

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Novartis building

Novartis to issue stark warning to UK at crisis meeting

Says UK needs to address decline in pharma R&D

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

Eisai: Bucking the trend with R&D growth

PME’s emerging companies series continues with a firm that’s committed to research as it expands its commercial position

- PMLiVE

Novartis gets US approval for Flucelvax flu jab made in cells

First vaccine approved that does not rely on use of fertilised chicken eggs for production

- PMLiVE

Roche’s Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

Novartis building

CHMP backs Novartis’ Bexsero, Exjade

European recommendations for meningitis vaccine and thalassaemia treatment

- PMLiVE

Lilly takes Xeljanz rival baricitinib into phase III

Its partner Incyte says baricitinib could become the number one JAK inhibitor for RA

- PMLiVE

New hope for castration-resistant prostate cancer

An unprecedented number of therapies have reached late-stage clinical trials or been approved over recent years targeting this disease with an unmet medical need

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links